Congestion Continues In Private Label Mucinex Pipeline; Court Rules Against Mutual
This article was originally published in The Tan Sheet & The Rose Sheet
Executive Summary
A ruling for RB n Pennsylvania federal court comes as it girds for increased competition from additional guaifenesin expectorant formulations that are the equivalents of Mucinex brand products and that Perrigo is marketing under license from manufacturer Allergan.
You may also be interested in...
Mutual Alleges Mucinex Monopoly In Extended-Release Guaifenesin
Mutual Pharmaceutical alleges in an antitrust suit that RB attempts to monopolize the extended-release guaifenesin OTC category with its Mucinex product. The suit says Mutual has lost “tens of millions” due to RB's failure to honor a contract to supply an “authorized generic” of the product.
Hemp Supplement Sales Continue In US Without FDA Acknowledgement As Lawful Products
Decision, explained by Principal Deputy Commissioner Woodcock, turns page on FDA’s 2019 announcement, after hemp was de-scheduled in 2018 farm bill, it would consider rulemaking for lawful use of hemp in supplements.
Improving US FDA Food Programs Starts At Top, Former Senior Agency Officials Say
Former acting commissioner Stephen Ostroff and Sharon Lindan Mayl, previously a senior advisor to FDA commissioner on food programs, say Reagan-Udall report was accurate in finding that establishing food program leadership with defined authorities is key to improving the programs, which include regulation of supplement manufacturing and marketing.